ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
386,458 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNO Stock News Headlines

Bionomics ADR (BNOX) Earnings Dates & Reports
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Bionomics Ltd: Bionomics' Half-Year Report
Will Bionomics (ASX:BNO) Spend Its Cash Wisely?
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Quarterly Activities Report for September 2022
Bionomics Investor Webinar
Bionomics Limited (BNO.AX)
Bionomics' Half-Year Report
Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to...
See More Headlines
Receive BNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2019
Today
4/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-24,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.02 million
Book Value
A$0.03 per share

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
2.13
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Adrian Hinton BEC (Age 70)
    F.C.A., Financial Controller
    Comp: $323.78k
  • Dr. Spyridon Papapetropoulos M.D. (Age 50)
    Ph.D., CEO, Pres & Director
  • Mr. Timothy M. Cunningham CPA (Age 60)
    CPA, M.B.A., Chief Financial Officer
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Dr. Julie Kerner Ph.D.
    Sr. VP of Bus. Operations
  • Dr. Atul R. Mahableshwarkar DFAPA
    M.D., Acting Chief Medical Officer
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Sec.

BNO Stock Analysis - Frequently Asked Questions

How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) released its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share for the quarter.

What other stocks do shareholders of Bionomics own?
This page (ASX:BNO) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners